Picture loading failed.

Anti-CD37 therapeutic antibody (Pre-made Lilotomab biosimilar,Whole mAb ADC) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Lilotomab (formerly tetulomab, HH1)[1] is a murine monoclonal antibody against CD37, a glycoprotein which is expressed on the surface of mature human B cells. It was generated at the Norwegian Radium Hospital.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-313-1mg 1mg 3090
GMP-Bios-ab-313-10mg 10mg 21890
GMP-Bios-ab-313-100mg 100mg 148000
GMP-Bios-ab-313-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CD37 therapeutic antibody (Pre-made Lilotomab biosimilar,Whole mAb ADC)
INN Name Lilotomab
TargetCD37
FormatWhole mAb ADC
DerivationMouse
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2014
Year Recommended2015
CompaniesNordic Nanovector
Conditions Approvedna
Conditions ActiveFollicular lymphoma;Non-Hodgkin's lymphoma;Diffuse large B cell lymphoma
Conditions Discontinuedna
Development Techna